The limits on sales of Type 2 diabetes drugs tirzepatide and dulaglutide come after a 2023 regulation limited sales of semaglutide, which is sold under the band name Ozempic.
A new report says the prevalence of obesity increased faster during the COVID-19 pandemic than it did over the course of more than a decade beforehand, specifically in young adults.